Literature DB >> 2221583

Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs.

H Hoffmann1, M Siebeck, M Spannagl, M Weis, R Geiger, M Jochum, H Fritz.   

Abstract

We hypothesized that thrombin activation may play a prominent role in endotoxin-induced secondary organ failure, such as acute lung injury. To test this hypothesis, we administered a thrombin-specific inhibitor, recombinant hirudin, in endotoxemic pigs. The pigs were anesthetized, mechanically ventilated, and prepared with Swan-Ganz and extravascular lung water (EVLW) catheters. A total of 18 randomly selected animals received a pretreatment of 1,000 U/kg of hirudin, followed by a continuous infusion over 6 h of 500 U/kg/h given simultaneously with the infusion of 10 micrograms/kg/h of Salmonella abortus equi endotoxin. Another 18 animals received a continuous infusion over 6 h of endotoxin but did not receive hirudin. All animals were fluid resuscitated with 17 ml/kg/h of saline for the duration of the experiment. Data are expressed as the mean (95% confidence interval). Hirudin reduced the endotoxin-induced consumption of plasma fibrinogen from -110 (-138 to -82) mg/100 ml to -39 (-67 to -12) mg/100 ml (p = 0.0001) and endotoxin-induced increases in the soluble fibrin in plasma from 434 (369 to 499) ng/ml to 236 (171 to 300) ng/ml (p = 0.0002). These data suggest an effective inhibition of the endotoxin-generated thrombin by hirudin. Furthermore, hirudin significantly reduced endotoxin-induced increases in pulmonary vascular resistance from 32 (27 to 37) kdyn x s x cm-5 x kg to 20 (15 to 25) kdyn x s x cm-5 x kg (p = 0.0015) and increases in EVLW from 15.4 (13.2 to 17.6) ml/kg to 12.2 (10.0 to 14.4) ml/kg (p = 0.0299).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2221583     DOI: 10.1164/ajrccm/142.4.782

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

Review 1.  Hirudin, a new therapeutic tool?

Authors:  J Bichler; H Fritz
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

Review 2.  Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome.

Authors:  Sara C Sebag; Julie A Bastarache; Lorraine B Ware
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

3.  Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.

Authors:  D C Howell; N R Goldsack; R P Marshall; R J McAnulty; R Starke; G Purdy; G J Laurent; R C Chambers
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

4.  Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS).

Authors:  Malgorzata Wygrecka; Philipp Markart; Ludger Fink; Andreas Guenther; Klaus T Preissner
Journal:  Thorax       Date:  2007-05-04       Impact factor: 9.139

5.  Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1.

Authors:  R C Chambers; K Dabbagh; R J McAnulty; A J Gray; O P Blanc-Brude; G J Laurent
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

6.  Expression profiling of genes regulated by Fra-1/AP-1 transcription factor during bleomycin-induced pulmonary fibrosis.

Authors:  Subbiah Rajasekaran; Narsa M Reddy; Wei Zhang; Sekhar P Reddy
Journal:  BMC Genomics       Date:  2013-06-07       Impact factor: 3.969

Review 7.  Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis.

Authors:  Ricardo J José; Andrew Williams; Ari Manuel; Jeremy S Brown; Rachel C Chambers
Journal:  Eur Respir Rev       Date:  2020-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.